Uses In vitro Targets
ChemicalBook > CAS DataBase List > GW 6471

GW 6471

Uses In vitro Targets
Product Name
GW 6471
CAS No.
880635-03-0
Chemical Name
GW 6471
Synonyms
GW 6471;GW 6471 USP/EP/BP;GW6471, 10 mM in DMSO;GW 6471, PPAR alpha antagonist;(S,Z)-N-(3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-((4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-yl)amino)propyl)propionamide;N-[(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}-2-{[(2Z)-4-oxo-4-[4-(trifluoromethyl)phenyl]but-2-en-2-yl]amino}propyl]propanamide;N-((2S)-2-(((1Z)-1-METHYL-3-OXO-3-(4-(TRIFLUOROMETHYL)PHENYL)PROP-1-ENYL)AMINO)-3-(4-(2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHOXY)PHENYL)PROPYL)PROPANAMIDE;Propanamide, N-[(2S)-2-[[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propen-1-yl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]-;[(2S)-2-[[(1Z)-1-METHYL-3-OXO-3-[4-(TRIFLUOROMETHYL)PHENYL]-1-PROPENYL]AMINO]-3-[4-[2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY]PHENYL]PROPYL]-CARBAMIC ACID ETHYL ESTER
CBNumber
CB4207232
Molecular Formula
C35H36F3N3O4
Formula Weight
619.67
MOL File
Mol file
More
Less

GW 6471 Property

Density 
1.204±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: 15 mg/mL
form 
solid
pka
15.90±0.46(Predicted)
color 
off-white
InChIKey
TYEFSRMOUXWTDN-DYQICHDWSA-N
SMILES
C(NC[C@@H](N/C(/C)=C\C(=O)C1=CC=C(C(F)(F)F)C=C1)CC1=CC=C(OCCC2=C(C)OC(C3=CC=CC=C3)=N2)C=C1)(=O)CC
More
Less

Safety

Hazard Codes 
Xi
Risk Statements 
36/37/38
Safety Statements 
26-36
WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
G5045
Product name
GW6471
Purity
≥98% (HPLC)
Packaging
5mg
Price
$289
Updated
2025/07/31
Cayman Chemical
Product number
11697
Product name
GW 6471
Purity
≥98%
Packaging
1mg
Price
$44
Updated
2024/03/01
Cayman Chemical
Product number
11697
Product name
GW 6471
Purity
≥98%
Packaging
5mg
Price
$151
Updated
2024/03/01
Cayman Chemical
Product number
11697
Product name
GW 6471
Purity
≥98%
Packaging
10mg
Price
$235
Updated
2024/03/01
Cayman Chemical
Product number
11697
Product name
GW 6471
Purity
≥98%
Packaging
25mg
Price
$533
Updated
2024/03/01
More
Less

GW 6471 Chemical Properties,Usage,Production

Uses

GW 6471 is a potent antagonist of PPARα with IC50 of 0.24 μM.

In vitro

GW6471 completely inhibits GW409544-induced activation of PPARα with IC50 of 0.24 μM. GW6471 at concentration ranging from 0.001-10 μM disrupts the interactions between PPAR and coactivator motifs derived from SRC-1 or CBP, but promotes the binding of the co-repressor motifs from SMRT or N-CoR. GW6471 adopts a U-shaped configuration and wraps around C276 of helix 3, destroys the integrity of the charge clamp but leaves sufficient space to accommodate the additional helical turn of the co-repressor motif in the PPAR/GW6471/SMRT complexes. [1] GW6471 at concentration of 10 μM significantly prevents cardiomyocyte differentiation and results in the reduced expression of cardiac sarcomeric proteins (ie α-actinin, troponin-T) and specific genes (ie α-MHC, MLC2v) in a time-dependent manner through inhibiting PPARα.

Targets

PPARα

Uses

GW 6471 is a peroxisome proliferator-activated receptor α (PPARα) antagonist. GW 6471 has been shown to enhance the binding affinity of the PPARα ligand-binding domain to the co-repressor proteins SMRT and NCoR.

General Description

GW6471 prevents apoptosis and cell cycle arrest at G0/G1 in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.

Biochem/physiol Actions

GW6471 is a PPARα antagonist, which completely inhibits GW409544-induced activation of PPARα with an IC50 = 0.24 μM. GW6471 induces a PPARα conformation that interacts efficiently with co-repressors.

in vivo

To test the antitumor activity of PPARα antagonism in vivo, a subcutaneous xenograft mouse model is used. Caki-1 cells are implanted subcutaneously in nude (Nu/Nu) mice. After tumor masses reach ～5 mm in diameter, GW6471 is administrated intraperitoneally every other day for 4 wk at a dose (20 mg/kg mouse body wt) that is described to be effective in an in vivo dose-response study and confirmed here to be efficacious. There are significant differences in tumor growth between vehicle- and GW6471-treated animals. No toxicity is observed at the doses of GW6471 based on weights of the animals, and laboratory values, including kidney and liver function tests, are not adversely affected. To demonstrate on-target effects of GW6471, c-Myc levels are evaluated in the tumors, which show significant decreases in the GW6471-treated animals[3].

IC 50

PPARα

storage

Store at +4°C

GW 6471 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

GW 6471 Suppliers

Canada 1 China 119 Switzerland 1 United Kingdom 1 United States 9 Global 131
SIGMA-RBI
Tel
--
Fax
--
Country
Switzerland
ProdList
6896
Advantage
91

880635-03-0, GW 6471Related Search:

GW 4064 GW843682, 5-(5,6-Dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide GW-6604 Carbamic acid, N-[(5S)-5-[[(2R,3S)-3-(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]-, phenylmethyl ester GW 627368X GW806742X

  • N-((2S)-2-(((1Z)-1-METHYL-3-OXO-3-(4-(TRIFLUOROMETHYL)PHENYL)PROP-1-ENYL)AMINO)-3-(4-(2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHOXY)PHENYL)PROPYL)PROPANAMIDE
  • [(2S)-2-[[(1Z)-1-METHYL-3-OXO-3-[4-(TRIFLUOROMETHYL)PHENYL]-1-PROPENYL]AMINO]-3-[4-[2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY]PHENYL]PROPYL]-CARBAMIC ACID ETHYL ESTER
  • GW 6471
  • Propanamide, N-[(2S)-2-[[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propen-1-yl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]-
  • GW 6471 USP/EP/BP
  • (S,Z)-N-(3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-((4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-yl)amino)propyl)propionamide
  • N-[(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}-2-{[(2Z)-4-oxo-4-[4-(trifluoromethyl)phenyl]but-2-en-2-yl]amino}propyl]propanamide
  • GW 6471, PPAR alpha antagonist
  • GW6471, 10 mM in DMSO
  • 880635-03-0
  • C35H36F3N3O4
  • Aromatics
  • Heterocycles
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • GW 6471